Kezar Life Sciences (KZR)
(Delayed Data from NSDQ)
$0.53 USD
-0.02 (-3.73%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $0.52 -0.01 (-1.61%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Kezar Life Sciences, Inc. [KZR]
Reports for Purchase
Showing records 1 - 20 ( 37 total )
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Zetomipzomib Timelines Look Promising; 2Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Adjusting Model Assumptions to Reflect Market Dynamics; Lowering PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
KZR-261 Data YE24; Zetomipzomib in Focus, With Data Mid-2026; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Eyes Still on 2026 PALIZADE Data Release; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Chinese Authorization for PALIZADE Lupus Nephritis Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Zetomipzomib Cleared for Clinical Assessment in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Zetomipzomib Clinical Timeline; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Restructuring Lengthens Runway; Management Changes; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Everest Medicines Deal Underscores Zetomipzomib Value; Raising PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Financial Results Reported; Modulating PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Initial Protein Secretion Data in 2H23; 1Q23 Financials; Lowering PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
R&D Day Highlights; 2022 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Financial Results; Sec61 Inhibitor Data at SITC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Complete Phase 2 Lupus Nephritis Data Continue to Impress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Kidney Week - Filtering Through The Abstracts For Upcoming Meeting
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Zetomipzomib New Phase 2a Hepatitis Trial; R&D Day 4Q22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Anti-CD19 CAR-T Lupus Data Do Not Threaten Our Thesis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Financial Results Reported; Raising PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Updated Phase 2 Data in Lupus Nephritis Continue to Impress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R